Georgia's Online Cancer Information Center

Find A Clinical Trial

Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

Status
Active
Cancer Type
Solid Tumor
Unknown Primary
Trial Phase
Phase I
Eligibility
18 - 100 Years, Male and Female
Study Type
Treatment
NCT ID
NCT04185883
Protocol IDs
20190135 (primary)
NCI-2020-00134
2023-506794-35
Study Sponsor
Amgen, Inc.

Summary

To evaluate the safety and tolerability of sotorasib administered in investigational
regimens in adult participants with KRAS p.G12C mutant advanced solid tumors.

Eligibility

  1. Men or women greater than or equal to 18 years old.
  2. Pathologically documented, locally-advanced or metastatic malignancy with, KRAS p.G12C mutation identified through molecular testing performed according to in-country requirements. In the United States, this test must be performed in a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University


1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.